ZA931489B - Use of interleuken-10 to suppress graft-vs-host disease - Google Patents

Use of interleuken-10 to suppress graft-vs-host disease

Info

Publication number
ZA931489B
ZA931489B ZA931489A ZA931489A ZA931489B ZA 931489 B ZA931489 B ZA 931489B ZA 931489 A ZA931489 A ZA 931489A ZA 931489 A ZA931489 A ZA 931489A ZA 931489 B ZA931489 B ZA 931489B
Authority
ZA
South Africa
Prior art keywords
interleuken
host disease
suppress graft
graft
suppress
Prior art date
Application number
ZA931489A
Inventor
Maria-Grazia Roncarolo
Rene De Waal Malefyt
Rosa Bacchetta
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA931489B publication Critical patent/ZA931489B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA931489A 1992-03-04 1993-03-02 Use of interleuken-10 to suppress graft-vs-host disease ZA931489B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84620892A 1992-03-04 1992-03-04

Publications (1)

Publication Number Publication Date
ZA931489B true ZA931489B (en) 1993-10-28

Family

ID=25297256

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA931489A ZA931489B (en) 1992-03-04 1993-03-02 Use of interleuken-10 to suppress graft-vs-host disease

Country Status (11)

Country Link
EP (1) EP0629130A1 (en)
JP (1) JPH07504437A (en)
KR (1) KR950700079A (en)
CN (1) CN1079166A (en)
AU (1) AU679908B2 (en)
CA (1) CA2131524A1 (en)
IL (1) IL104916A0 (en)
MX (1) MX9301192A (en)
NZ (1) NZ249754A (en)
WO (1) WO1993017698A1 (en)
ZA (1) ZA931489B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510719A (en) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル Use of a pharmaceutical composition containing an effective amount of interleukin-10, its analogs and / or agonists
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
JPH10502249A (en) * 1994-07-05 1998-03-03 スティーノ・リサーチ・グループ・アクティーゼルスカブ Immunomodulator
WO1996029082A1 (en) * 1995-03-23 1996-09-26 Governors Of Dalhousie College And University A process of prolonging organ allograft survival
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
EP0845994A1 (en) * 1995-08-09 1998-06-10 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
WO1997026278A1 (en) 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
US6090413A (en) * 1996-03-25 2000-07-18 Lee; Timothy D. Process of prolonging organ allograft survival
WO1998010792A1 (en) * 1996-09-11 1998-03-19 Prendergast Patrick T Immune direction therapy
WO1998020033A2 (en) * 1996-11-06 1998-05-14 Schering Corporation RENATURATION AND PURIFICATION OF VIRAL INTERLEUKIN-10 (vIL-10)
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO1999030730A1 (en) * 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
EP1061949B1 (en) * 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
JP5008810B2 (en) 2000-04-11 2012-08-22 ユニバーシティ オブ サザン カリフォルニア Method for preventing transplant rejection using TGF-β to induce inhibitory T cells
CN105106214A (en) * 2015-08-05 2015-12-02 范国煌 Novel Lck small-molecule inhibitor for inhibiting graft-versus-host disease
SG10201606949QA (en) 2016-08-19 2018-03-28 Singapore Health Serv Pte Ltd Immunosuppressive composition for use in treating immunological disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same

Also Published As

Publication number Publication date
KR950700079A (en) 1995-01-16
JPH07504437A (en) 1995-05-18
WO1993017698A1 (en) 1993-09-16
NZ249754A (en) 1997-06-24
IL104916A0 (en) 1993-07-08
MX9301192A (en) 1994-08-31
CA2131524A1 (en) 1993-09-16
AU679908B2 (en) 1997-07-17
EP0629130A1 (en) 1994-12-21
CN1079166A (en) 1993-12-08
AU3732893A (en) 1993-10-05

Similar Documents

Publication Publication Date Title
HK1005985A1 (en) Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
GB2231265B (en) Therapeutic use of serotonin-antagonists
HU9300536D0 (en) Compounds of medical effect
ZA931489B (en) Use of interleuken-10 to suppress graft-vs-host disease
GB2255503B (en) Improved use of ß2-bronchodilator drugs
ZA931935B (en) Preparation of substituted guanidines
TW414158U (en) Construction of structural body
ZA914435B (en) Treatment of disease
ZA932553B (en) New use of B-carbolines
GB8925576D0 (en) Improvement related to personal hygiene
ZA935647B (en) Treatment of sickle cell disease
GB9218792D0 (en) Skin cleansing composition
EP0522157A4 (en) Novel use of alkanamidocarboxybetaine
ZA955931B (en) Optically active isomers of dihydrexidine and its substituted analogs
NZ250159A (en) Use of furan-3-carboxamides as microbicides
EP0553954A3 (en) Preparation of tetramethyldiamino-polyoxyethylenes
EP0444931A3 (en) Use of 3-oxygermylpropionic acid to treat and prevent diabetes-dependent autoimmune diseases
GB2266241B (en) Treatment of pastures
GB9216360D0 (en) Treatment of blood
ZA936136B (en) Treatment of skin diseases
HUT60804A (en) Limiting structure of increased voice-inhibition
EG20171A (en) Treatment of conditions and disease
GB9207595D0 (en) Treatment of pastures
GB9213862D0 (en) Medical use of enzymes
GB8829366D0 (en) Treatment of disease